CI vs. RGC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at CI and RGC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | CI | RGC |
|---|---|---|
| Company Name | The Cigna Group | Regencell Bioscience Holdings Limited |
| Country | United States | Hong Kong |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Pharmaceuticals |
| Market Capitalization | 80.28 billion USD | 6.07 billion USD |
| Exchange | NYSE | NasdaqCM |
| Listing Date | March 31, 1982 | July 16, 2021 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of CI and RGC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | CI | RGC |
|---|---|---|
| 5-Day Price Return | -0.45% | -3.94% |
| 13-Week Price Return | -3.81% | 17.22% |
| 26-Week Price Return | 1.19% | 12,700.00% |
| 52-Week Price Return | -13.19% | 5,995.24% |
| Month-to-Date Return | 12.48% | -3.03% |
| Year-to-Date Return | 8.92% | 9,746.15% |
| 10-Day Avg. Volume | 1.61M | 0.19M |
| 3-Month Avg. Volume | 1.84M | 2.18M |
| 3-Month Volatility | 30.32% | 642.38% |
| Beta | 0.47 | 2.33 |
Profitability
Return on Equity (TTM)
CI
12.27%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
CI’s Return on Equity of 12.27% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
RGC
-54.75%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
CI
1.92%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
CI’s Net Profit Margin of 1.92% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
RGC
--
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
Net Profit Margin data for RGC is currently unavailable.
Operating Profit Margin (TTM)
CI
3.41%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
CI’s Operating Profit Margin of 3.41% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
RGC
--
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
Operating Profit Margin data for RGC is currently unavailable.
Profitability at a Glance
| Symbol | CI | RGC |
|---|---|---|
| Return on Equity (TTM) | 12.27% | -54.75% |
| Return on Assets (TTM) | 3.26% | -51.38% |
| Net Profit Margin (TTM) | 1.92% | -- |
| Operating Profit Margin (TTM) | 3.41% | -- |
| Gross Profit Margin (TTM) | 9.86% | -- |
Financial Strength
Current Ratio (MRQ)
CI
0.79
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
CI’s Current Ratio of 0.79 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
RGC
42.68
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
Debt-to-Equity Ratio (MRQ)
CI
0.77
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
CI’s Debt-to-Equity Ratio of 0.77 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
RGC
0.00
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
CI
2.32
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
CI’s Interest Coverage Ratio of 2.32 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
RGC
--
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
Interest Coverage Ratio data for RGC is currently unavailable.
Financial Strength at a Glance
| Symbol | CI | RGC |
|---|---|---|
| Current Ratio (MRQ) | 0.79 | 42.68 |
| Quick Ratio (MRQ) | 0.68 | 41.89 |
| Debt-to-Equity Ratio (MRQ) | 0.77 | 0.00 |
| Interest Coverage Ratio (TTM) | 2.32 | -- |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
CI
1.97%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
CI’s Dividend Yield of 1.97% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
RGC
0.00%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
CI
31.63%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
CI’s Dividend Payout Ratio of 31.63% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
RGC
0.00%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | CI | RGC |
|---|---|---|
| Dividend Yield (TTM) | 1.97% | 0.00% |
| Dividend Payout Ratio (TTM) | 31.63% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
CI
16.09
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
CI’s P/E Ratio of 16.09 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
RGC
--
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for RGC is currently unavailable.
Price-to-Sales Ratio (TTM)
CI
0.31
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
CI’s P/S Ratio of 0.31 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
RGC
--
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
P/S Ratio data for RGC is currently unavailable.
Price-to-Book Ratio (MRQ)
CI
2.20
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
CI’s P/B Ratio of 2.20 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
RGC
9.57
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | CI | RGC |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 16.09 | -- |
| Price-to-Sales Ratio (TTM) | 0.31 | -- |
| Price-to-Book Ratio (MRQ) | 2.20 | 9.57 |
| Price-to-Free Cash Flow Ratio (TTM) | 12.49 | -- |